WARNING! More information in the Privacy Policy and the use of cookies Research and development The BIOTON Group, focused on innovation and development, looks for its opportunities in various scientific and research projects. The previous experience, a group of excellent specialists and the implementation of a long-term investment strategy enable opening to new areas of action, which are prospective and the most important for improving the quality of health and life of patients. The main research base of BIOTON SA has been the Institute of Biotechnology and Antibiotics since the Company was established. IBA is a leading research institute in Poland, employing highly qualified and experienced specialists. For over 50 years, IBA has been involved in basic research in the field of drug production by chemical synthesis and biosynthesis with the use of genetically modified organisms. BIOTON and the Institute of Biotechnology and Antibiotics conduct research on biotechnological products and new forms of drugs, and carry out a research program in the following areas: Genetic engineering: the work focuses on the search for new plasmids in wild-type bacterial strains, isolating them, creating sequence regions in them for gene cloning and constructing new expression vectors based on these plasmids. The aim of these works is to obtain the possibility of creating efficient, stable, genetically modified microorganisms, capable of industrial production of therapeutic protein substances. Biotechnology: the purpose of studying the processes of isolating and modifying proteins with a biological effect is to optimize the selection of methods for processing recombinant protein substances. Pharmacology: studies are conducted on the mechanisms of resistance of selected species of bacterial strains to antibiotics used in therapy, studies on the synthesis methods and properties of new anthracycline antibiotic derivatives, and studies on the pharmacokinetics and pharmacodynamics of medicinal substances. The research aims to develop new medicinal products and to create new research methods useful for their evaluation. The other companies belonging to the BIOTON Group also conduct research and development activities: BioPartners Holdings AG - strategic relationships, advanced cooperation with scientific experts and access to the most modern manufacturing plants enable the development of innovative drugs. The strategic R&D partners of BioPartners include, among others: LG Life Science – południowokoreańska spółka biotechnologiczna i nowoczesne centrum badawczo-rozwojowe, zajmujące się rozwojem biofarmaceutyków od 1982 r., Rentschler Biotechnologie – niemiecka firma specjalizująca się w rozwoju i produkcji biofarmaceutyków, w tym interferonów, oraz kontraktowym wytwarzaniu leków w różnych postaciach. Fisiopharma S.R.L. – spółka współpracuje z włoskimi ośrodkami uniwersyteckimi i innymi firmami farmaceutycznymi przy projektach badawczo-rozwojowych ukierunkowanych na innowacje i udoskonalenia technologii wytwórczych substancji czynnych oraz form gotowych leków odtwórczych. Medipolis GMP - Oulu - a company specializing in the production of GMP (Good Manufacturing Practice) microbial fermentation and offering the production and development of products for biotechnology companies. The company focuses on the production of biologically active substances (API Active Pharmaceutical Ingredients) on a small scale for clinical and toxicological purposes (therapeutic proteins, enzymes, therapeutic injections, DNA plasmids). The company meets the FDA and EMEA (European Medicines Agency) requirements for biopharmaceutical production and is an excellent production base for biotechnological products for clinical trials required in the registration processes at the EMEA and FDA. About company Mission of the company Authorities of BIOTON SA History of BIOTON SA Research and development Quality management Sales targets and global expansion Companies of the BIOTON SA Group Cooperation with the European Union Press office Privacy policy and the use of cookies contact AVAILABILITY OF GENSUPEN Press office Contact for media: Renata Ożarowska ozarowskar@bioton.pl Tel .: +22 721 40 02 Contact for investors: Renata Ożarowska ozarowskar@bioton.pl Tel .: +22 721 40 02 © 2016 BIOTON SA phone: +48 22 721 40 00 fax: +48 22 721 13 33 bioinfo@bioton.pl